Musculoskeletal Conditions
Regenerative Solutions for Musculoskeletal Conditions
Musculoskeletal conditions are among the most common reasons patients seek regenerative medicine. When cartilage wears down, tendons fail to heal, or discs degenerate, conventional medicine offers management — not repair. WJ-MSC Exosome therapy targets the underlying biology to restore function, reduce pain, and slow or reverse degeneration.
Knee Osteoarthritis
The Problem
Knee OA is the progressive breakdown of articular cartilage — the smooth tissue that allows bones to glide without friction. As cartilage erodes, bone grinds on bone, triggering chronic inflammation, pain, stiffness, and loss of mobility. Conventional options — NSAIDs, cortisone injections, hyaluronic acid, and eventual joint replacement — manage symptoms but do not address the underlying degeneration. Cortisone, in particular, accelerates cartilage breakdown with repeated use.
How WJ-MSC Exosomes Help
WJ-MSC Exosomes address knee OA through all four core mechanisms simultaneously. Anti-inflammatory cytokines (IL-10, TSG-6) reduce synovial inflammation and pain. VEGF restores blood flow to the subchondral bone. bFGF and TGF-β stimulate chondrocytes to produce new cartilage matrix. Immunomodulatory signals prevent the autoimmune component of OA from continuing to destroy joint tissue. Research shows measurable improvements in cartilage thickness, pain scores (VAS), and functional outcomes (WOMAC).
Evidence Snapshot
- Matas J, et al. (2019). Umbilical cord-derived MSCs for knee OA: a randomized controlled trial. Stem Cells Translational Medicine. Demonstrated significant improvement in VAS pain scores and WOMAC function.
- Pers YM, et al. (2016). Adipose MSCs for knee OA: dose-ranging study. Stem Cells Translational Medicine. Confirmed safety and dose-dependent efficacy of MSC intra-articular injection.
Tendon & Ligament Injuries
The Problem
Tendons and ligaments have notoriously poor blood supply, making them slow and incomplete healers. Chronic tendinopathy (rotator cuff, Achilles, patellar, lateral epicondyle) involves collagen disorganization, micro-tears, and failed healing cycles. Standard treatments — physical therapy, PRP, cortisone, and surgery — have inconsistent outcomes, and cortisone injections are associated with tendon rupture risk with repeated use.
How WJ-MSC Exosomes Help
WJ-MSC Exosomes address tendon pathology by secreting bFGF and PDGF to stimulate tenocyte proliferation and collagen synthesis, VEGF to restore vascular supply to the avascular tendon tissue, and anti-inflammatory signals to resolve the chronic low-grade inflammation that perpetuates tendinopathy. The result is organized collagen remodeling — replacing disorganized scar tissue with functional tendon matrix.
Evidence Snapshot
- Usuelli FG, et al. (2018). Adipose-derived MSCs for Achilles tendinopathy. Foot and Ankle Surgery. Showed significant pain reduction and ultrasound evidence of tendon remodeling.
- Pas HI, et al. (2017). Stem cell injections in knee tendons. British Journal of Sports Medicine. Systematic review confirming safety and preliminary efficacy of MSC injection for tendinopathy.
Degenerative Disc Disease
The Problem
Intervertebral discs are avascular structures that degenerate with age, injury, and mechanical stress. As the nucleus pulposus loses hydration and the annulus fibrosus develops tears, discs collapse — compressing nerves, causing chronic back and leg pain, and reducing spinal mobility. Conventional treatment ranges from pain management to spinal fusion, which eliminates motion at the treated level and accelerates degeneration at adjacent levels.
How WJ-MSC Exosomes Help
WJ-MSC Exosomes injected into the disc space secrete TGF-β and GDF-5 to stimulate nucleus pulposus cell proliferation and proteoglycan synthesis — restoring disc hydration and height. Anti-inflammatory signals reduce the cytokine-driven degeneration cycle. VEGF supports the endplate vascularity that nourishes the disc. Early clinical data shows disc height restoration and significant pain reduction in patients with Grade II–III Pfirrmann degeneration.
Evidence Snapshot
- Orozco L, et al. (2011). Intervertebral disc repair by autologous MSC transplantation. Transplantation. First clinical study demonstrating safety and disc height improvement with MSC injection for DDD.
- Noriega DC, et al. (2017). Intervertebral disc repair by allogeneic MSCs. Transplantation. Randomized controlled trial showing significant pain reduction and disc height maintenance.
Ready to Explore Treatment?
The next step is a comprehensive consultation with Melissa to review your imaging, health history, and goals.